A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure
Phase of Trial: Phase II
Latest Information Update: 18 Jan 2019
At a glance
- Drugs LIK 066 (Primary) ; Empagliflozin
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 04 Sep 2018 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2018 The study has been discontinued in Czech Republic.